Literature DB >> 20176260

Immunologic endocrine disorders.

Aaron W Michels1, George S Eisenbarth.   

Abstract

Autoimmunity affects multiple glands in the endocrine system. Animal models and human studies highlight the importance of alleles in HLA-like molecules determining tissue-specific targeting that, with the loss of tolerance, leads to organ-specific autoimmunity. Disorders such as type 1A diabetes, Graves disease, Hashimoto thyroiditis, Addison disease, and many others result from autoimmune-mediated tissue destruction. Each of these disorders can be divided into stages beginning with genetic susceptibility, environmental triggers, active autoimmunity, and finally metabolic derangements with overt symptoms of disease. With an increased understanding of the immunogenetics and immunopathogenesis of endocrine autoimmune disorders, immunotherapies are becoming prevalent, especially in patients with type 1A diabetes. Immunotherapies are being used more in multiple subspecialty fields to halt disease progression. Although therapies for autoimmune disorders stop the progress of an immune response, immunomodulatory therapies for cancer and chronic infections can also provoke an unwanted immune response. As a result, there are now iatrogenic autoimmune disorders arising from the treatment of chronic viral infections and malignancies. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20176260      PMCID: PMC2835296          DOI: 10.1016/j.jaci.2009.09.053

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  85 in total

1.  Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives.

Authors:  P Achenbach; K Warncke; J Reiter; A J K Williams; A G Ziegler; P J Bingley; E Bonifacio
Journal:  Diabetologia       Date:  2006-09-26       Impact factor: 10.122

2.  Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.

Authors:  Ajay V Maker; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Marybeth Hughes; Michael J Yellin; Leah R Haworth; Catherine Levy; Tamika Allen; Sharon A Mavroukakis; Peter Attia; Steven A Rosenberg
Journal:  J Immunother       Date:  2006 Jul-Aug       Impact factor: 4.456

3.  Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.

Authors:  Mario Salvi; Guia Vannucchi; Irene Campi; Nicola Currò; Davide Dazzi; Simona Simonetta; Paola Bonara; Stefania Rossi; Clara Sina; Claudio Guastella; Roberto Ratiglia; Paolo Beck-Peccoz
Journal:  Eur J Endocrinol       Date:  2007-01       Impact factor: 6.664

4.  B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.

Authors:  Daniel El Fassi; Claus H Nielsen; Steen J Bonnema; Hans C Hasselbalch; Laszlo Hegedüs
Journal:  J Clin Endocrinol Metab       Date:  2007-02-06       Impact factor: 5.958

5.  Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes.

Authors:  Jill M Norris; Xiang Yin; Molly M Lamb; Katherine Barriga; Jennifer Seifert; Michelle Hoffman; Heather D Orton; Anna E Barón; Michael Clare-Salzler; H Peter Chase; Nancy J Szabo; Henry Erlich; George S Eisenbarth; Marian Rewers
Journal:  JAMA       Date:  2007-09-26       Impact factor: 56.272

6.  Role of CD28 in fatal autoimmune disorder in scurfy mice.

Authors:  Nagendra Singh; Phillip R Chandler; Yoichi Seki; Babak Baban; Mayuko Takezaki; David J Kahler; David H Munn; Christian P Larsen; Andrew L Mellor; Makio Iwashima
Journal:  Blood       Date:  2007-04-26       Impact factor: 22.113

Review 7.  Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.

Authors:  T Staeva-Vieira; M Peakman; M von Herrath
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

8.  Defective regulatory and effector T cell functions in patients with FOXP3 mutations.

Authors:  Rosa Bacchetta; Laura Passerini; Eleonora Gambineri; Minyue Dai; Sarah E Allan; Lucia Perroni; Franca Dagna-Bricarelli; Claudia Sartirana; Susanne Matthes-Martin; Anita Lawitschka; Chiara Azzari; Steven F Ziegler; Megan K Levings; Maria Grazia Roncarolo
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

9.  Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.

Authors:  Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes.

Authors:  John A Todd; Neil M Walker; Jason D Cooper; Deborah J Smyth; Kate Downes; Vincent Plagnol; Rebecca Bailey; Sergey Nejentsev; Sarah F Field; Felicity Payne; Christopher E Lowe; Jeffrey S Szeszko; Jason P Hafler; Lauren Zeitels; Jennie H M Yang; Adrian Vella; Sarah Nutland; Helen E Stevens; Helen Schuilenburg; Gillian Coleman; Meeta Maisuria; William Meadows; Luc J Smink; Barry Healy; Oliver S Burren; Alex A C Lam; Nigel R Ovington; James Allen; Ellen Adlem; Hin-Tak Leung; Chris Wallace; Joanna M M Howson; Cristian Guja; Constantin Ionescu-Tîrgovişte; Matthew J Simmonds; Joanne M Heward; Stephen C L Gough; David B Dunger; Linda S Wicker; David G Clayton
Journal:  Nat Genet       Date:  2007-06-06       Impact factor: 38.330

View more
  23 in total

Review 1.  The multiple faces of autoimmune-mediated bone loss.

Authors:  Georg Schett; Jean-Pierre David
Journal:  Nat Rev Endocrinol       Date:  2010-11-02       Impact factor: 43.330

2.  Presence of more activating KIR genes is associated with Hashimoto's thyroiditis.

Authors:  Elham Ashouri; Mohammad Hossein Dabbaghmanesh; Gholamhossein Ranjbar Omrani
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

3.  Levothyroxine monotherapy versus levothyroxine and selenium combination therapy in chronic lymphocytic thyroiditis.

Authors:  L Yu; L Zhou; E Xu; Y Bi; X Hu; X Pei; G Jin
Journal:  J Endocrinol Invest       Date:  2017-05-22       Impact factor: 4.256

4.  Ultrasound findings of the thyroid gland in children and adolescents.

Authors:  Elena Moschos; Hans-Joachim Mentzel
Journal:  J Ultrasound       Date:  2022-02-09

5.  TRPV2 POLYMORPHISMS INCREASE OR REDUCE THE RISK OF TYPE 2 DIABETES - HASHIMOTO THYROIDITIS COMORBIDITY.

Authors:  F Bulut Arikan; F A Özdemir; D Şen; S Erdem; S Yörübulut; H Doğan; L Keskin
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

6.  Protein Tyrosine Phosphatase Non-receptor 22 Gene C1858T Polymorphism in Patients with Coexistent Type 2 Diabetes and Hashimoto's Thyroiditis.

Authors:  Funda Bulut; Deniz Erol; Halit Elyas; Halil Doğan; Fethi Ahmet Ozdemir; Lezan Keskin
Journal:  Balkan Med J       Date:  2014-03-01       Impact factor: 2.021

7.  Lipid peroxidation, proteins modifications, anti-oxidant enzymes activities and selenium deficiency in the plasma of hashitoxicosis patients.

Authors:  Malek Mseddi; Riadh Ben Mansour; Fatma Mnif; Bochra Gargouri; Mohamed Abid; Fadhel Guermazi; Hamadi Attia; Saloua Lassoued
Journal:  Ther Adv Endocrinol Metab       Date:  2015-10       Impact factor: 3.565

Review 8.  Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases?

Authors:  Philippa Marrack; John W Kappler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

9.  Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer.

Authors:  L L Cunha; R C Ferreira; M A Marcello; J Vassallo; L S Ward
Journal:  J Thyroid Res       Date:  2011-02-17

10.  Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's disease.

Authors:  Simon H S Pearce; Anna L Mitchell; Stuart Bennett; Phil King; Sukesh Chandran; Sath Nag; Shu Chen; Bernard Rees Smith; John D Isaacs; Bijay Vaidya
Journal:  J Clin Endocrinol Metab       Date:  2012-07-05       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.